Victor J. Hruby, Ph.D.
University of Arizona
Lab developed Melanotan II; foundational figure in melanotropin peptide chemistry.
Melanotan II is a cyclic, non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R) developed in 1989 in the laboratory of Victor J. Hruby at the University of Arizona. It has been studied for pigmentation biology, energy balance, central melanocortin signaling, and behavioral pathways. It is the precursor from which bremelanotide (PT-141) was derived.
Mechanism of action
- Cyclic α-MSH analog activating MC1R (pigmentation), MC3R/MC4R (energy and behavior).
- Stimulates eumelanin production via MC1R engagement.
- Central melanocortin activity influences appetite, energy expenditure, and sexual behavior pathways.
Research highlights
- Developed in 1989 by the Hruby lab at the University of Arizona.
- Foundational chemistry led to the FDA-approved compound bremelanotide (PT-141).
- Extensive structure-activity work in the peer-reviewed melanotropin design literature.